| Literature DB >> 31814876 |
Mustafa Barbaros Düzgün1,2, Konstantinos Theofilatos3, Alexandros G Georgakilas4, Athanasia Pavlopoulou1,2.
Abstract
Application of heat above 43°C and up to 47°C, the so-called "thermal ablation" range, leads to tumor cell destruction either by apoptosis or by necrosis. However, tumor cells have developed mechanisms of defense that render them thermoresistant. Of importance, the in situ application of heat for the treatment of localized solid tumors can also prime specific antitumor immunity. Herein, a bioinformatic approach was employed for the identification of molecular determinants implicated in thermoresistance and immunogenic cell death (ICD). To this end, both literature-derived (text mining) and microarray gene expression profile data were processed, followed by functional enrichment analysis. Two important functional gene modules were detected in hyperthermia resistance and ICD, the former including members of the heat shock protein (HSP) family of molecular chaperones and the latter including immune-related molecules, respectively. Of note, the molecules HSP90AA1 and HSPA4 were found common between thermoresistance and damage signaling molecules (damage-associated molecular patterns (DAMPs)) and ICD. In addition, the prognostic potential of HSP90AA1 and HSPA4 overexpression for cancer patients' overall survival was investigated. The results of this study could constitute the basis for the strategic development of more efficient and personalized therapeutic strategies against cancer by means of thermotherapy, by taking into consideration the genetic profile of each patient.Entities:
Mesh:
Year: 2019 PMID: 31814876 PMCID: PMC6878812 DOI: 10.1155/2019/4606219
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Venn diagram of the thermoresistance and DAMP/ICD-associated molecules.
Overrepresented WikiPathways of (a) DAMP/ICD and (b) thermoresistance-associated genes.
| DAMP/ICD | ||
| WikiPathways | Gene symbol | Adj. |
|
| ||
| Cytokines and inflammatory response | IFNG, TNF, IL10, CD4, IL1B, IL6, IL12B | 1.29 |
| Inflammatory response pathway | IFNG, CD80, IL2RA, CD86, TNFRSF1A | 8.18 |
| Toll-like receptor signaling pathway | TNF, CD80, IL1B, CD86, IL6, IL12B | 3.01 |
| Allograft rejection | IFNG, TNF, CD80, IL10, CD86, IL12B | 3.01 |
| Regulation of toll-like receptor signaling pathway | TNF, CD80, IL1B, CD86, IL6, IL12B | 1.15 |
| Selenium pathway | IFNG, TNF, IL1B, IL6, ICAM1 | 1.47 |
| TCR signaling pathway | CD8A, CD4, IL1B, IL6 | 1.06 |
| TNF alpha signaling pathway | TNF, HSP90AA1, IL6, TNFRSF1A | 1.06 |
| Th1-Th2 | IL10, IL12B | 1.49 |
| SIDS susceptibility pathways | TNF, IL10, IL1B, IL6 | 1.49 |
| Alzheimer's disease | TNF, IL1B, TNFRSF1A | 2.52 |
| Type II interferon signaling (IFNG) | IFNG, IL1B, ICAM1 | 2.52 |
| Senescence and autophagy | IFNG, IL1B, IL6 | 7.51 |
| Monoamine transport | TNF, IL1B | 0.0002 |
| NOD pathway | HSP90AA1, IL1B | 0.0003 |
| AhR pathway | TNF, HSP90AA1 | 0.0003 |
| TSLP signaling pathway | IL2RA, IL6 | 0.0004 |
| TWEAK signaling pathway | TNF, IL6 | 0.0005 |
| TGF beta signaling pathway | IFNG, TNF | 0.0006 |
|
| ||
| Thermoresistance | ||
| WikiPathways | Gene symbol | Adj. |
|
| ||
| Parkin-ubiquitin proteasomal system pathway | HSPA4, HSPA1A, HSPA1B, HSPA4 | 7.81 |
| Prostate cancer | JUN, PLK1, ABCC4, FOS, HSP90AB1 | 0.0001 |
| FAS pathway and stress induction of HSP regulation | JUN, RB1, HSPB1 | 0.0005 |
| MAPK signaling pathway | JUN, HSPB1, FOS, HSPA1A | 0.0005 |
| Integrated pancreatic cancer pathway | JUN, PLK1, EGR1, HSP90AB1 | 0.0006 |
| TSH signaling pathway | JUN, RB1, FOS | 0.0006 |
| Androgen receptor signaling pathway | JUN, RB1, BAG1 | 0.0009 |
| Oncostatin M signaling pathway | JUN, EGR1, FOS | 0.0009 |
| Drug induction of bile acid pathway | ABCC4, ABCB1 | 0.0009 |
Average estimated melting temperature for thermoresistance and DAMP/ICD proteins.
| Thermoresistant proteins | DAMP/ICD proteins | |
|---|---|---|
| Average melting temperature | 67°C | 63.42°C |
| Percentage of denaturated proteins at 45°C | 0.00% | 0.00% |
| Percentage of denaturated proteins at 50°C | 0.00% | 12.5% |
| Percentage of denaturated proteins at 55°C | 3.03% | 16.67% |
| Percentage of denaturated proteins at 60°C | 6.06% | 33.33% |
Figure 2Network modules of the most highly connected genes related to (a) thermoresistance and (b) DAMPs/ICD. The nodes represent genes/proteins and the connecting lines (edges) functional links, respectively. The edges connecting the nodes indicate the mode of action of the interacting molecules with a confidence score above 0.7. The molecules implicated in the relevant WikiPathways are underlined.
Figure 3Differential expression of (a) HSPA1A, (b) HSP90AB1, (c) BAG1, (d, e) HSP90AA1, (f–h) HSPA4, and (i, j) DNAJB5 in different cancers. BRCA: breast invasive carcinoma; LGG: brain lower grade glioma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; THYM: thymoma; UCS: uterine carcinosarcoma.
Figure 4Survival graphs representing the prognostic potential of HSP90AA1 for overall survival in (a) prostate adenocarcinoma and (b) kidney renal clear cell and HSPA4 for OS in (c) head and neck squamous cell carcinoma and (d) breast invasive carcinoma. The HRs with the corresponding 95% confidence interval values (within parentheses) and p values are indicated.